{"doi":"10.1002/cncr.33148","title":"Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial","abstract":"BACKGROUND: We previously reported on a phase 2 study of everolimus plus bevacizumab across various nonclear cell renal cell carcinoma (nccRCC) histologies and observed encouraging activity among patients with papillary RCC (pRCC) and unclassified RCC (uRCC) with a major papillary component. We subsequently expanded the study to enroll additional patients with pRCC variants. METHODS: Everolimus plus bevacizumab was administered at standard doses until disease progression or intolerance to therapy. The primary endpoint was the 6-month progression-free survival (PFS) rate; secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Correlative analyses included next-generation sequencing (NGS) from tumor and germline across >341 genes of interest. RESULTS: In addition to 19 patients with pRCC variants in the original cohort, 20 patients with similar features were enrolled on the expansion cohort (uRCC with papillary features [n = 24], pRCC [n = 14], and translocation-associated RCC with papillary features [n = 1]). Among 37 evaluable patients, the 6-month PFS rate was 78%, the median PFS was 13.7 months (95% CI, 10.8-16.4 months), and the ORR was 35%. With a median follow-up of 17.6 months, the median OS was 33.9 months (95% CI, 23.3-71.9). Tolerance was consistent with prior reports for everolimus plus bevacizumab. NGS results (n = 33) identified responses in patients with a wide spectrum of genomic alterations, including ARID1A, FH, and MET mutations. CONCLUSION: The expansion cohort results confirm robust activity of everolimus plus bevacizumab in metastatic pRCC variants, supporting this regimen as a standard option for this patient population.","journal":"Cancer","year":2020,"id":94426,"datarank":1.2468830160411717,"base_score":3.6635616461296463,"endowment":3.6635616461296463,"self_citation_contribution":0.5495342469194471,"citation_network_contribution":0.6973487691217246,"self_endowment_contribution":0.5495342469194471,"citer_contribution":0.6973487691217246,"corpus_percentile":null,"corpus_rank":null,"citation_count":38,"citer_count":34,"citers_with_citation_signal":30,"citers_with_endowment":30,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9571,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":314355,"name":"Yasser Ged","orcid":"0000-0001-6671-7002","position":1,"is_corresponding":false},{"id":470240,"name":"Chung‐Han Lee","orcid":"0000-0001-5511-0635","position":2,"is_corresponding":false},{"id":470241,"name":"Andrea Knežević","orcid":"0000-0002-0741-2150","position":3,"is_corresponding":false},{"id":354016,"name":"Ana M. Molina","orcid":"0000-0003-2025-9418","position":4,"is_corresponding":false},{"id":249413,"name":"Ying‐Bei Chen","orcid":"0000-0001-5207-3648","position":5,"is_corresponding":false},{"id":470242,"name":"Joshua Chaim","orcid":"0000-0001-9413-7507","position":6,"is_corresponding":false},{"id":470243,"name":"Devyn Taylor Coskey","orcid":"0000-0003-1663-2398","position":7,"is_corresponding":false},{"id":470244,"name":"Samuel Murray","orcid":"0000-0003-0074-6462","position":8,"is_corresponding":false},{"id":325595,"name":"Satish K. Tickoo","orcid":"0000-0002-9775-0478","position":9,"is_corresponding":false},{"id":14429,"name":"Victor E. Reuter","orcid":"0000-0002-7593-1016","position":10,"is_corresponding":false},{"id":470245,"name":"Sujata Patil","orcid":"0000-0003-1706-5321","position":11,"is_corresponding":false},{"id":470246,"name":"Han Xiao","orcid":"0000-0001-8231-4246","position":12,"is_corresponding":false},{"id":470829,"name":"Jahan Aghalar","orcid":null,"position":13,"is_corresponding":false},{"id":470830,"name":"Arlyn Apollo","orcid":null,"position":14,"is_corresponding":false},{"id":337832,"name":"Maria I. Carlo","orcid":"0000-0002-4786-7408","position":15,"is_corresponding":false},{"id":226686,"name":"Robert J. Motzer","orcid":"0000-0001-6925-2327","position":16,"is_corresponding":false},{"id":289279,"name":"Martin H. Voss","orcid":"0000-0003-0551-5807","position":17,"is_corresponding":false},{"id":90735,"name":"Darren R. Feldman","orcid":"0000-0003-2424-4635","position":0,"is_corresponding":true}],"reference_count":36,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-18T22:32:04.778261Z","pmid":"32975815","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}